CURRENT RESEARCH ACTIVITY
RETINA Retinal vein occlusion: • Early predictors of one-year outcomes of eyes with retinal vein occlusion treated with Vascular Endothelial Growth Factor (VEGF) inhibitors • Near-infrared light photobiomodulation treatment for retinal vein occlusion macular oedema - currently recruiting - supported by Australian Vision Research grant Age related macular degeneration: • Effect of switching eyes with neovascular age related macular degeneration to faricimab from other antiVEGF agents Diabetic retinopathy • Treatment of diabetic macular oedema with faricimab using a pragmatic approach - comparing fixed dosing with treat and extend regimen • Genetic study of patients with history of treatment for diabetic retinopathy • 5-year outcomes of eyes with diabetic macular oedema treated with antiVEGF • Outcomes of eyes with diabetic macular edema treated with anti-vascular endothelial growth factor in clinical practice - Cochrane Eye vision analysis Macular telangiectasia type 2: • Macular Telangiectasia (MacTel) Natural History Observation and Registry Study (NHOR) – genetic study of patients and family members with MacTel CATARACT SURGERY • Long-term visual acuity and adverse event outcomes for new generation refractive extended depth of focus intraocular lenses • Magnitude of postoperative refractive astigmatism compared to preoperative corneal astigmatism in eyes with 0.50 D to 1.50 D of astigmatism implanted with TECNIS Toric IOL Model ZCT100 • Manual versus automated marking systems for intraoperative management or corneal astigmatism • Capturing a Snapshot of Perioperative Patient Education and Consent for Cataract Surgery in NSW Public Clinics GLAUCOMA • Intraocular pressure (IOP) – Impact of intravitreal injections on glaucoma incidence and progression INDUSTRY SPONSORED TRIALS • A Phase 3 study comparing aflibercept 2mg to aflibercept 8mg in eyes with macular oedema due to retinal vein occlusion (Quasar; Bayer) • A Phase 3 study comparing aflibercept 2mg to aflibercept 8mg in eyes with neovascular age related macular degeneration (Pulsar; Bayer) • Evaluation of a port delivery system refilled every 6-9 months with ranibizumab in eyes with neovascular age related macular degeneration (Velodrome; ROCHE) • An extension study of the Phase 3, RHINE multicentre, randomised, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with diabetic macular edema (Rhone-X; ROCHE) • An extension study of the Phase 3 study LUCERNE to evaluate the efficacy and safety of faricimab in participants with neovascular age related macular degeneration (Avonelle-X; ROCHE) • Phase 2 Study to assess safety and efficacy of multiple doses of IONIS-FB-LRx given subcutaneously in participants with geographic atrophy secondary to age-related macular degeneration (GOLDEN; IONIS/ROCHE) • Phase 2 study of Danicopan given orally versus placebo in eyes with geographic atrophy (PHOENIX; Alexion)
36
Made with FlippingBook - professional solution for displaying marketing and sales documents online